Stockscreener 앱 받기
4.62
0.86%
-0.04
시간 외 거래:
4.42
-0.20
-4.33%
전일 마감가:
$4.66
열려 있는:
$4.55
하루 거래량:
351.75K
Relative Volume:
1.50
시가총액:
$86.41M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+13.24%
1개월 성능:
+81.18%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$4.34
$4.85
1주일 범위
$3.75
$7.26
52주 변동 폭
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
명칭
Kalaris Therapeutics Inc
전화
650-249-2727
주소
628 MIDDLEFIELD ROAD, PALO ALTO
KLRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
4.62 | 87.15M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-07-23 | 재개 | Piper Sandler | Neutral |
| 2025-05-07 | 개시 | Leerink Partners | Outperform |
| 2025-04-08 | 개시 | William Blair | Outperform |
Kalaris Therapeutics Inc 주식(KLRS)의 최신 뉴스
Kalaris Therapeutics Inc. stock trend outlook and recovery pathMarket Sentiment Report & Technical Pattern Alert System - Newser
Can a trend reversal in Kalaris Therapeutics Inc. lead to recoveryJuly 2025 EndofMonth & Real-Time Stock Movement Alerts - Newser
Is Kalaris Therapeutics Inc. impacted by rising ratesMarket Volume Summary & Low Risk High Win Rate Stock Picks - خودرو بانک
Is Kalaris Therapeutics Inc. a good stock for dollar cost averagingMarket Sentiment Report & Short-Term Trading Alerts - خودرو بانک
Forecasting Kalaris Therapeutics Inc. price range with options dataWeekly Trade Summary & Weekly High Return Forecasts - Newser
Momentum divergence signals in Kalaris Therapeutics Inc. chartQuarterly Performance Summary & Risk Adjusted Swing Trade Ideas - Newser
What’s the recovery path for long term holders of Kalaris Therapeutics Inc.Quarterly Portfolio Report & Consistent Growth Stock Picks - Newser
Can Kalaris Therapeutics Inc. Overcome Bearish SentimentDividend Hike & Verified Technical Signals - beatles.ru
What data driven models say about Kalaris Therapeutics Inc.’s futureJuly 2025 Setups & Technical Confirmation Trade Alerts - Newser
Using data models to predict Kalaris Therapeutics Inc. stock movement2025 Price Targets & Weekly High Return Opportunities - Newser
Volatility clustering patterns for Kalaris Therapeutics Inc.Index Update & Accurate Entry/Exit Alerts - Newser
What earnings revisions data tells us about Kalaris Therapeutics Inc.Earnings Recap Report & Fast Entry Momentum Alerts - Newser
Will Kalaris Therapeutics Inc. bounce back from current supportQuarterly Trade Summary & Verified Short-Term Plans - Newser
Key metrics from Kalaris Therapeutics Inc.’s quarterly dataBuy Signal & Accurate Buy Signal Notifications - Newser
Can Kalaris Therapeutics Inc. stock outperform in a bear market2025 Trading Volume Trends & Safe Capital Investment Plans - خودرو بانک
What’s Kalaris Therapeutics Inc.’s historical return2025 Bull vs Bear & Expert Curated Trade Setups - خودرو بانک
How does Kalaris Therapeutics Inc. compare to its peersPortfolio Profit Report & Precise Entry and Exit Recommendations - خودرو بانک
Is Kalaris Therapeutics Inc. stock risky to hold now2025 Market Overview & Verified Chart Pattern Signals - خودرو بانک
Kalaris Eyes A Game-Changing Breakthrough In Anti-VEGF Therapy With TH103 To Treat retinal Disease - RTTNews
Using data filters to optimize entry into Kalaris Therapeutics Inc.Trade Risk Assessment & High Win Rate Trade Alerts - Newser
Kalaris (KLRS.O) Surges 13%—What's Driving the Intraday Move? - AInvest
Raymond James Initiates Coverage on Strong Buy, PT $23 with Kalaris - AInvest
Kalaris Therapeutics Peeks Ahead: Strong Cash Reserves Empower Vital Trials - StocksToTrade
Kalaris Therapeutics shares surge 32.38% intraday after Zacks and Raymond James upgrade ratings and merger completion. - AInvest
Kalaris Therapeutics, Inc.Common Stock (Nasdaq:KLRS) Stock Quote - FinancialContent
Is Kalaris Therapeutics Inc. stock reversal real or fake2025 Year in Review & Smart Money Movement Tracker - Newser
Chart overlay techniques for tracking Kalaris Therapeutics Inc.2025 Institutional Moves & Weekly Watchlist for Consistent Profits - Newser
Raymond James Initiates Kalaris Therapeutics at Strong Buy - MarketScreener
Does Kalaris Therapeutics Inc. fit your quant trading modelIndex Update & Weekly Breakout Stock Alerts - Newser
Top chart patterns to watch in Kalaris Therapeutics Inc.2025 EndofYear Setup & High Return Stock Watch Alerts - Newser
Using Bollinger Bands to evaluate Kalaris Therapeutics Inc.Portfolio Risk Summary & Breakout Confirmation Alerts - Newser
Recap Report: Is Kalaris Therapeutics Inc. stock risky to hold nowJuly 2025 Summary & AI Powered Market Entry Strategies - خودرو بانک
How sensitive is Kalaris Therapeutics Inc. to inflationWeekly Market Outlook & Free Community Consensus Stock Picks - خودرو بانک
Analyzing Kalaris Therapeutics Inc. with multi timeframe chartsIndex Update & Accurate Entry/Exit Alerts - Newser
Kalaris Therapeutics Inc. recovery potential after sell offJuly 2025 Catalysts & Verified Momentum Stock Ideas - Newser
Will Kalaris Therapeutics Inc. benefit from rising consumer demandWeekly Market Summary & Detailed Earnings Play Alerts - خودرو بانک
Why is Kalaris Therapeutics Inc. stock going upJuly 2025 Levels & Daily Momentum Trading Reports - خودرو بانک
Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know - sharewise.com
Kalaris Therapeutics Inc. Matches Institutional Buying FilterWeekly Profit Summary & Stepwise Swing Trade Plans - beatles.ru
What MACD signals say about Kalaris Therapeutics Inc.Layoff News & Risk Controlled Stock Pick Alerts - Newser
Will Kalaris Therapeutics Inc. stock go up soon2025 Historical Comparison & Stepwise Trade Signal Implementation - Newser
Kalaris Therapeutics Inc (KLRS) 재무 분석
Kalaris Therapeutics Inc (KLRS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):